Objective: To investigate the factors affecting progno- sis of patients with primary hepatocellular carcinoma (PHC) after resection. Methods: From 1976 to 1992, 213 patients with PHC treated with hepatectomy were foll...Objective: To investigate the factors affecting progno- sis of patients with primary hepatocellular carcinoma (PHC) after resection. Methods: From 1976 to 1992, 213 patients with PHC treated with hepatectomy were followed up for more than 5 years. Thirty-one of the patients who had sur- vived for more than 5 years were compared with 56 patients who had survived for less than 5 years. Results: Early detection of tumor, radical resection, number of tumors, capsule formation, operation safe distance, presence of portal tumor embolus, pre- sence of cirrhosis and tumor size were important fac- tors affecting the prognosis of patients with PHC. The proportion of small liver cancer in the patients who had survived for more than 5 years was greatly larger than that in the control group. Conclusions: Early detection of tumor and radical re- section are of value in raising the 5-year survival rate. Much remains to be investigated about the rela- tionship between safe margin distance and prognosis of patients with PHC.展开更多
目的以Meta分析的方法定量评估HER-2/neu基因扩增/或表达增强状态与上皮性卵巢癌患者手术后的中位生存期和5年生存率的关联性。方法检索、筛选1989年以来所有论述HER-2/neu状态与患者预后关系的中、英文回顾性研究文献。在Ludwig中心符...目的以Meta分析的方法定量评估HER-2/neu基因扩增/或表达增强状态与上皮性卵巢癌患者手术后的中位生存期和5年生存率的关联性。方法检索、筛选1989年以来所有论述HER-2/neu状态与患者预后关系的中、英文回顾性研究文献。在Ludwig中心符号轶(Centered signed rank)和DerSimonian-Laird等方法基础上对各研究提供的生存数据进行统计分析。结果共纳入25篇文献,3251例患者。HER-2/neu表达率为27.1%[95%CI(0,54.8%)],与病理分期、分型和分级无关。HER-2/neu阳性者中位生存期平均减少0.65年,5年生存率下降[HR=1.22,95%CI(1.09,1.36)]。亚组分析显示,HER-2/neu蛋白表达与预后关系最明确,强阳性者5年内死亡风险增加,且对铂类化疗药物的反应性减低。结论在妇科肿瘤临床中,将HER-2/neu作为常规的病理指标使用,有助于进行合理的预后评估,并制定个体化化疗方案。展开更多
目的观察程序性死亡因子1(programmed death 1,PD-1)在乳腺癌中的表达,探讨其表达与临床病理特征的相关性。方法利用Western blot法检测高侵袭性人乳腺癌细胞系MDA-MB-231和低侵袭性人乳腺癌细胞系MCF-7中PD-1蛋白的表达,采用免疫组化En...目的观察程序性死亡因子1(programmed death 1,PD-1)在乳腺癌中的表达,探讨其表达与临床病理特征的相关性。方法利用Western blot法检测高侵袭性人乳腺癌细胞系MDA-MB-231和低侵袭性人乳腺癌细胞系MCF-7中PD-1蛋白的表达,采用免疫组化En Vision两步法检测71例乳腺癌组织中PD-1的表达及其与患者5年生存率之间的关系。结果 MDA-MB-231中PD-1的蛋白表达明显高于MCF-7(P<0.05)。PD-1在乳腺癌实质中的阳性率为61.2%(44/71),乳腺癌间质中浸润淋巴细胞PD-1阳性率为71.3%(51/71),两者表达有相关性(P<0.05),PD-1表达与乳腺癌组织学分级、肿瘤大小、淋巴结转移呈正相关(P<0.05),PD-1阳性患者术后5年生存率(61.3%)低于阴性患者(94.1%)。但与乳腺癌患者年龄、ER、PR、HER-2及Ki-67水平均无明显相关(P>0.05)。结论 PD-1可能成为乳腺癌生物学行为和预后的重要潜在标志物。展开更多
文摘Objective: To investigate the factors affecting progno- sis of patients with primary hepatocellular carcinoma (PHC) after resection. Methods: From 1976 to 1992, 213 patients with PHC treated with hepatectomy were followed up for more than 5 years. Thirty-one of the patients who had sur- vived for more than 5 years were compared with 56 patients who had survived for less than 5 years. Results: Early detection of tumor, radical resection, number of tumors, capsule formation, operation safe distance, presence of portal tumor embolus, pre- sence of cirrhosis and tumor size were important fac- tors affecting the prognosis of patients with PHC. The proportion of small liver cancer in the patients who had survived for more than 5 years was greatly larger than that in the control group. Conclusions: Early detection of tumor and radical re- section are of value in raising the 5-year survival rate. Much remains to be investigated about the rela- tionship between safe margin distance and prognosis of patients with PHC.
文摘目的以Meta分析的方法定量评估HER-2/neu基因扩增/或表达增强状态与上皮性卵巢癌患者手术后的中位生存期和5年生存率的关联性。方法检索、筛选1989年以来所有论述HER-2/neu状态与患者预后关系的中、英文回顾性研究文献。在Ludwig中心符号轶(Centered signed rank)和DerSimonian-Laird等方法基础上对各研究提供的生存数据进行统计分析。结果共纳入25篇文献,3251例患者。HER-2/neu表达率为27.1%[95%CI(0,54.8%)],与病理分期、分型和分级无关。HER-2/neu阳性者中位生存期平均减少0.65年,5年生存率下降[HR=1.22,95%CI(1.09,1.36)]。亚组分析显示,HER-2/neu蛋白表达与预后关系最明确,强阳性者5年内死亡风险增加,且对铂类化疗药物的反应性减低。结论在妇科肿瘤临床中,将HER-2/neu作为常规的病理指标使用,有助于进行合理的预后评估,并制定个体化化疗方案。
